On March 23, 2022 DURECT Corporation (Nasdaq: DRRX) reported that Dr. James E. Brown, President and CEO, will be participating in a panel discussion at the Cantor Virtual Rare Orphan Disease Summit hosted by Kristen Kluska, Managing Director, Biotechnology Research Analyst of Cantor Fitzgerald (Press release, DURECT, MAR 23, 2022, https://investors.durect.com/news-releases/news-release-details/durect-corporation-present-2022-cantor-fitzgerald-virtual-rare [SID1234610912]). The title of the panel is "Small but Mighty: Innovative Strategies in Tackling Some of the Larger Rare Orphan Disease Markets" and will take place at 1:00 pm ET on Wednesday, March 30, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

If you have interest in participating in the Cantor Virtual Rare Orphan Disease Summit, please reach out to your Cantor Fitzgerald representative.